Ranbaxy Laboratories Articles
India's Ranbaxy posts 23% sales growth for 2012
26 February 2013
Indian pharmaceuticals market led by Ranbaxy in terms of revenue
31 January 2013
Ranbaxy Labs' Absorica debuts in USA
27 November 2012
Ranbaxy Labs beats estimates, as 3rd-qtr sales leap 31%
9 November 2012
Ranbaxy gains approval for new manufacturing plant in Malaysia
14 September 2012
US FDA pulls 27 Ranbaxy ANDAs approvals under consent decree
23 August 2012
Ranbaxy gains US FDA approval for Absorica
29 May 2012
Ranbaxy sales rocket 55%, net rises four-fold
11 May 2012
Daiichi Sankyo and Ranbaxy launch Sevikar in Romania
19 April 2012
Teva debuts generic of Provigil, Avapro and Avalide; Ranbaxy Crestor copy OKed in Canada
1 April 2012
Ranbaxy opens new plant in Morocco
12 March 2012
Ranbaxy posts $586 million loss due to charges
23 February 2012
Department of Justice seeks permanent injunction against Ranbaxy
27 January 2012
Ranbaxy signs consent decree with US FDA over production practices
22 December 2011
Payers’ outlook for Pfizer’s Lipitor generic strategy not rosy; second Caduet copy launched by Ranbaxy
6 December 2011
Watson and Ranbaxy kick off genericization of Lipitor, launching their approved copies in USA
1 December 2011
India’s Ranbaxy posts 3rd-qtr 2011 loss
10 November 2011
Ranbaxy debuts first approved generic of Nexium in the UK
5 September 2011
Ranbaxy posts 2nd-qtr 2011 net profit down 25%
7 August 2011
First-quarter FY 2012 net profit at Takeda jumps 18%, while that at Daiichi Sankyo slumps 23.5%
2 August 2011
Ranbaxy and Mylan unit to make and market three Gilead HIV drugs in developing countries
13 July 2011
Merck KGaA US units agree $44.3 million settlement with DoJ; Ranbaxy faces up to $1 billion fine?
5 May 2011
Japan’s Daiichi Sankyo says nine-month 2010 sales boosted by Ranbaxy, but sees 4th-qtr loss due to interest costs at the Indian unit
1 February 2011
Takeda settles Actos patent law suits with Mylan, Watson and Ranbaxy, as well as Teva and others
22 December 2010
Abbott Labs files suit against Impax over Simcor patent challenge; Ranbaxy debuts generic Aricept in USA
29 November 2010
Ranbaxy 3rd-qtr 2010 net profit rockets 168% as sales rise 13%
12 November 2010
Outlook for generic equivalent of Pfizer’s Lipitor; how will US exclusivity resolve? asks law firm HPM
14 October 2010
Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
2 September 2010
Daiichi Sankyo to leverage Ranbaxy’s Romania and South Africa presence to market Tavanic
21 July 2010
Ranbaxy launches branded generic prasugrel in India
10 June 2010
Daiichi Sankyo to expand scope in Japan, setting up new generics unit with affiliate Ranbaxy
1 March 2010
Ranbaxy back in black in fourth quarter as US sales soar
26 February 2010
Daiichi Sankyo ups profit forecast by 13% on expected rupee gain related to Ranbaxy; files flu drug in Japan
1 February 2010
India’s Ranbaxy to enter vaccines market in deal with Biovel
19 January 2010
Ranbaxy to launch Daiichi Sankyo’s olmesartan in six African markets
23 December 2009
UK regulatory agency clears prostate drug Flomax for OTC use; generic competition due next year in USA
14 December 2009
Big upside for Ranbaxy as it launches generic version of Glaxos herpes drug Valtrex
27 November 2009
Japanese drug majors deliver mixed first-half results
2 November 2009
PPD to acquire Excel PharmaStudies, hives off compounding business and invests in Celtic
28 October 2009
India’s Ranbaxy and Dr Reddy’s post strong results
27 October 2009
Japan stock market week to May 25, 2009
27 May 2009
Daiichi swings to loss on Ranbaxy buyout
27 May 2009
Diapharm organizes GMP inspection at Ranbaxy
13 May 2009
Ranbaxy plant OKed by UK/Australian agencies
30 March 2009
Daiichi will pay off Ranbaxy drop for 20 years
16 March 2009
Japan stock market week to March 2, 2009
9 March 2009
US FDA says Ranbaxy falsified data
9 March 2009
Ranbaxy buy knocks Daiichi into loss
16 February 2009
Japanese stock prices week to Feb 2, 2009
9 February 2009
Daiichi offers to buy further 20% in Zenotech
26 January 2009
Pharma/biotech mergers and acquisitions in 2008
12 January 2009
Japan stock market week to Jan 5, 2009
12 January 2009
Daiichi to book a $3.8B loss on Ranbaxy buy
12 January 2009
Debiopharm files complete response to FDA for Sanvar
24 November 2008
Ranbaxy swings to $81.4M loss in 3rd-qtr
17 November 2008
Daiichi Sankyo's tender offer for Ranbaxy successful
27 October 2008
CORRECTION: US ban on Indian-sourced drugs
6 October 2008
Sun Pharma says 2008 US growth will be 25%
6 October 2008
NY Mayor Giuliani hired by Ranbaxy
29 September 2008
Ranbaxy responds to FDA allegations
29 September 2008
FDA bans imports from two Ranbaxy facilities
22 September 2008
Indian firms worried over US Ranbaxy case
11 August 2008
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
